Outgrowth of a TKI-resistant clone after clearance of the T790M-positive subclone was associated with shorter mPFS in NSCLC patients who tended to have a smaller fraction of T790M over the activating EGFR mutation in their tumor at baseline [30,109,110]. The gene discussed is EGFR; the disease is neoplasm.